OCLN and colitis: This effect persisted to a lesser but still significant extent during the resolution phase of colitis on day 7 post-DNBS challenge, with reductions in ZO-1 (77% *** p < 0.001 vs. vehicle) and occludin (75% *** p < 0.001 vs. vehicle).